Clinical trial NCT00087867: Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
Official title: An Open-label Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed, Refractory Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
SCIO-469
p38 MAP kinase
myeloma
bone marrow
Lead sponsor: Scios, Inc.
Sponsor class: INDUSTRY
First posted: 2004-07-19
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.

Detailed description: The main objective of this study is to assess the efficacy of SCIO-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates. Patients took SCIO-469 two capsules (60 mg) by mouth three times a day with water, preferably with a meal, for 72 days except on Days 1 and 30 of monotherapy and Days 1 and 11 of combination therapy. On these days, the second dose of SCIO-469 was administered after collection of the 12-hour PK sample, and the third dose was not administered.

Eligibility criteria: Inclusion Criteria:

* Life expectancy more than three months
* diagnosed with multiple myeloma (MM)
* relapsed following a response to any conventional MM therapy, and refractory to their most recent MM therapy
* Karnofsky performance status = 60
* no electrocardiographic evidence of acute ischemia or new conduction system abnormalities
* no history of myocardial infarction within last 6 months
* serum concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3X upper limit of normal (ULN)
* total serum bilirubin = 2X ULN
* Calculated or measured creatinine clearance \>30 mL/min
* platelet count = 30 x 10(9)/L
* hemoglobin concentration = 8 g/dL
* white blood cell count = 2.0 x 10(9)/L

Exclusion Criteria:

* Patients with non-secretory myeloma, plasma cell leukemia, or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes)
* major surgery within four weeks of enrollment
* severe elevated serum calcium
* heart failure
* receipt of chemotherapy within 21 days before enrollment, receiving immunotherapy, radiation therapy, or other investigational agents
* receipt of corticosteroids equivalent to more than 10 mg/day of prednisone within two weeks before enrollment
* known allergies to agents used in bortezomib (e.g., boron or mannitol)
* poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol

Primary outcomes:
measure: Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.
timeFrame: Day 73
Secondary outcomes:
measure: Time to first response, time to best response, and percentage of patients with disease progression were assessed.
timeFrame: Days 1, 15, 30, 52, and 73
measure: Size and number of lytic bone lesions were summarized.
timeFrame: screening and Day 73
measure: Quality of life and pain was assessed.
timeFrame: Days 1, 15,30,52,73
measure: Performance status was evaluated.
timeFrame: Screening, Days 1, 30, 73
measure: Bone disease was monitored by assessing various markers.
timeFrame: Days 1, 15, 30, 52, 73
Other outcomes:
Locations:
Study officials:
affiliation: Scios, Inc.
name: Scios, Inc. Clinical Trial
role: STUDY_DIRECTOR
References: